One in 10 Americans now use GLP-1 drugs for weight loss. Is this the tipping point for Ozempic era?

What began as a treatment for type 2 diabetes has rapidly evolved into one of the biggest shifts in modern healthcare. New data suggests that GLP-1 medications, popularly associated with brands such as Ozempic and Wegovy, are no longer confined to celebrity headlines or specialist clinics but have entered the mainstream.

According to a new Gallup survey, 11% of US adults now say they are currently taking a GLP-1 medication for weight loss, up sharply from just 3% in 2024. Even more striking, 15% say they have used one at some point, underscoring how quickly these medicines have become part of everyday healthcare conversations.

More from Health

The findings reflect a broader shift in how obesity is being treated, and how society increasingly views weight management.

From diabetes drug to household name

GLP-1 receptor agonists were originally developed to help people with type 2 diabetes regulate blood sugar. Researchers soon noticed another effect: patients were losing significant amounts of weight because the drugs slow stomach emptying, reduce appetite and increase feelings of fullness.

That discovery transformed medicines such as semaglutide and tirzepatide into some of the most sought-after obesity treatments in the world. Today, doctors prescribe them not only for diabetes but also for obesity in eligible patients, alongside lifestyle changes. The Gallup poll suggests that this transition is happening at remarkable speed.

A treatment that's becoming increasingly mainstream

Just two years ago, using GLP-1 drugs for weight loss was still relatively uncommon. Today, roughly one in every 10 American adults reports currently taking one for that purpose.

Other surveys point in the same direction. A recent poll by the non-profit health policy organisation KFF found that around one in eight US adults is currently taking a GLP-1 medication for weight loss, diabetes or another medical condition, while nearly one in five has tried one at some point.

The growing demand has also fuelled discussions around affordability, insurance coverage and long-term access, with many patients still finding the drugs prohibitively expensive despite expanding reimbursement programmes.

Beyond the weighing scale

The impact of GLP-1 medicines is extending well beyond doctors' clinics. As more people use these medications, researchers and businesses are beginning to observe shifts in consumer behaviour. Food companies are reformulating products to appeal to changing appetites, while retailers are monitoring changes in spending patterns linked to weight loss and healthier eating habits.

Health data is also beginning to hint at broader population-level effects. Gallup has previously reported that US obesity rates have shown signs of declining after reaching record highs in 2022, although experts caution that several factors, including greater use of GLP-1 drugs, may be contributing to the trend. A direct cause-and-effect relationship has not been established.

Is America getting less obese?

The rise in GLP-1 drugs appears to coincide with another notable trend.

According to Gallup, the US adult obesity rate has fallen to 36.4% in 2026, down from a record 39.9% in 2022. The polling agency notes that the decline has tracked inversely with the growing use of GLP-1 medications across the country, although the survey does not establish that the drugs are solely responsible for the drop. Other factors, including changes in diet, physical activity and healthcare access, may also play a role.

At the same time, the percentage of Americans who report having been diagnosed with diabetes has remained broadly stable since 2023 after climbing steadily for around 15 years. Gallup notes that because diabetes is a lifelong condition that can be managed but not cured, a fall in obesity rates would be expected to slow the rise in diabetes rather than immediately reduce the number of people living with the disease.

The findings are based on responses from more than 10,000 US adults surveyed between February and June 2026. Gallup calculates obesity using the standard body mass index (BMI) threshold of 30 or above, relying on respondents' self-reported height and weight. While self-reported figures may slightly underestimate obesity because people often overstate their height or understate their weight, Gallup says the methodology has remained consistent over time, making it useful for tracking long-term trends.

They're not a magic solution

Despite the enthusiasm, health specialists continue to stress that GLP-1 medications are not a substitute for healthy habits.  Current medical guidance recommends them as part of a broader treatment plan that includes dietary changes, physical activity and ongoing medical supervision. They are generally prescribed for people with obesity or for those who are overweight with obesity-related health conditions.

The drugs can also cause side effects, including nausea, vomiting and gastrointestinal discomfort, particularly when treatment begins. Research has also found that many patients regain a significant portion of the weight they lose after discontinuing therapy, highlighting that obesity often requires long-term management rather than a short-term intervention.

What it could mean for the rest of the world

Although the latest figures are specific to the United States, they offer a glimpse into a broader global trend. Demand for GLP-1 therapies has surged across several countries, including India, where awareness has grown rapidly as newer obesity treatments become available and clinicians increasingly recognise obesity as a chronic medical condition rather than simply a lifestyle issue.

For healthcare systems, the challenge now is balancing the promise of these drugs with questions around affordability, equitable access and long-term care. As more evidence emerges on their benefits, and limitations, the conversation is likely to move beyond celebrity transformations towards public health.

The latest Gallup figures suggest that moment may already have arrived. GLP-1 drugs are no longer a niche therapy. They are becoming part of mainstream medicine, and their influence is beginning to reach far beyond the clinic.